[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana.
Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.
|
[3] |
XIA Lanfang, LI Keli, WANG Lei, LI Yan, WANG Huaqing.
Impact of comparator selection on signal detection in adverse events following immunization in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 798-804.
|
[4] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|
[5] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[6] |
ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui.
One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305.
|
[7] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[8] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[9] |
CHEN Shuang, ZHENG Shufen, ZHANG Shuyao, ZHONG Shilong.
Adverse reactions of tumor immunotherapy drugs—PD-1/PD-L1 inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1107-1112.
|
[10] |
TAN Jing, LIU Chunrong, HUANG Shiyao, GAO Pei, WANG Yang, LI Chen, HE Yong, YUAN Hong, WANG Wen, LI Ling, XIONG Yiquan, REN Yan, YAO Minghong, ZHAO Yan, DONG Fang, SHEN Chuanyong, SUN Xin.
Expert consensus on post-marketing risk monitoring technology for high-risk implantable passive medical devices based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 13-17.
|
[11] |
ZHENG Chao, WU Yan, ZHANG Lan, HU Kai, ZENG Ye, WANG Wen, WANG Ling.
Methods for risk trend analysis of EU post-marketing surveillance for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 79-82.
|
[12] |
MAO Zhenbin, LIU Shuyu.
Implications of Regulatory Science for the Construction of Medical Device Vigilance Systems
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 601-605.
|
[13] |
Chen Aihong, Yin Qiangbing, Li Huadan, Wu Nengjian.
Analysis of Monitoring Reports on Suspected Adverse Events Following Immunization in Pingshan District Shenzhen City during 2015~2018
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 464-468.
|
[14] |
JU Shan, LIU Yinghui, WANG Yawen, TENG Yingying, JIANG Yan, DENG Gang, SUN Lei.
Clinical Evaluation of Medical Devices Seen from International Coordination Documents
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1062-1065.
|
[15] |
LI Xinxu, TANG Zhimin, ZHOU Jun, WANG Jun.
Limitations of the Safety Assessment in Premarketing Clinical Trials of Drugs and Suggestions for Improvement
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 465-470.
|